James E Flynn - Net Worth and Insider Trading

James E Flynn Net Worth

The estimated net worth of James E Flynn is at least $3.7 Billion dollars as of 2024-06-13. James E Flynn is the of Nuvalent Inc and owns about 19,991,024 shares of Nuvalent Inc (NUVL) stock worth over $1.6 Billion. James E Flynn is the of AveXis Inc and owns about 2,236,700 shares of AveXis Inc (AVXS) stock worth over $487 Million. James E Flynn is also the of Larimar Therapeutics Inc and owns about 21,231,974 shares of Larimar Therapeutics Inc (LRMR) stock worth over $204 Million. Besides these, James E Flynn also holds AdaptHealth Corp (AHCO) , Shockwave Medical Inc (SWAV) , Mirum Pharmaceuticals Inc (MIRM) , Antares Pharma Inc (ATRS) , Audentes Therapeutics Inc (BOLD) , Revolution Medicines Inc (RVMD) , XenoPort Inc (XNPT) , Edgewise Therapeutics Inc (EWTX) , Alpine Immune Sciences Inc (ALPN) , Avadel Pharmaceuticals PLC (AVDL) , Arena Pharmaceuticals Inc (ARNA) , Rhythm Pharmaceuticals Inc (RYTM) , NxStage Medical Inc (NXTM) , Schrodinger Inc (SDGR) , Arvinas Inc (ARVN) , Constellation Pharmaceuticals Inc (CNST) , Vanda Pharmaceuticals Inc (VNDA) , Axogen Inc (AXGN) , Kiniksa Pharmaceuticals Ltd (KNSA) , Cabaletta Bio Inc (CABA) , Regenxbio Inc (RGNX) , Terns Pharmaceuticals Inc (TERN) , PepGen Inc (PEPG) , Nkarta Inc (NKTX) , Invuity Inc (IVTY) , Editas Medicine Inc (EDIT) , Annexon Inc (ANNX) , eHealth Inc (EHTH) , Catalyst Biosciences Inc (CBIO) , Rigel Pharmaceuticals Inc (RIGL) , SteadyMed Ltd (STDY) , CAS Medical Systems Inc (CASM) , Xeris Biopharma Holdings Inc (XERS) , Black Diamond Therapeutics Inc (BDTX) , Aclaris Therapeutics Inc (ACRS) , Generation Bio Co (GBIO) , Singular Genomics Systems Inc (OMIC) , Xilio Therapeutics Inc (XLO) , Societal CDMO Inc (SCTL) , Lumos Pharma Inc (LUMO) , CalciMedica Inc (CALC) , CytomX Therapeutics Inc (CTMX) , Alimera Sciences Inc (ALIM) , Syros Pharmaceuticals Inc (SYRS) , Proteon Therapeutics Inc (PRTO) , Neos Therapeutics Inc (NEOS) , Streamline Health Solutions Inc (STRM) , Frequency Therapeutics Inc (FREQ) , Oncorus Inc (ONCR) , Acutus Medical Inc (AFIB) , Homology Medicines Inc (FIXX) , Mallinckrodt PLC (MNKKQ) , Zafgen Inc (ZFGN) , aTyr Pharma Inc (ATYR) , Cyclacel Pharmaceuticals Inc (CYCC) , Dynavax Technologies Corp (DVAX) , The Medicines Co (MDCO) , Davis Select U.S. Equity ETF (DUSA) . Details can be seen in James E Flynn's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that James E Flynn has not made any transactions after 2024-03-12 and currently still holds the listed stock(s).

Transaction Summary of James E Flynn

To

James E Flynn Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James E Flynn owns 85 companies in total, including Oncorus Inc (ONCR) , Larimar Therapeutics Inc (LRMR) , and CalciMedica Inc (CALC) among others .

Click here to see the complete history of James E Flynn’s form 4 insider trades.

Insider Ownership Summary of James E Flynn

Ticker Comapny Transaction Date Type of Owner
ONCR Oncorus Inc 2022-12-30 director & 10 percent owner & other: *Possible Member of 10% Group
LRMR Larimar Therapeutics Inc 2024-02-16 10 percent owner & other: Possible Member of 10% Group
CALC CalciMedica Inc 2020-09-29 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2021-07-19 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2020-07-28 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-07-21 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2020-07-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-06-16 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2021-01-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-03-13 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2020-02-18 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-02-10 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-02-03 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-01-30 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2019-11-08 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2019-10-29 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-10-07 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2022-06-06 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-06-27 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-03-11 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-02-11 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-10-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-07-23 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-07-23 10 percent owner & other: Possible member of 10% group
LIMIT LIMIT 2018-06-25 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2014-10-21 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-05-29 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2018-05-09 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2018-03-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-10-10 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-06-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-04-27 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-01-26 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-12-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-09-23 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-06-23 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-07-25 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-07-21 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-07-06 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-02-19 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-02-17 director & 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-02-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-12-17 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-12-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-10-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-09-30 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-09-22 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-07-28 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-05-12 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-03-25 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-02-11 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2014-11-21 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2014-08-06 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2014-07-30 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2014-04-22 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2012-12-04 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2011-05-26 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2011-04-06 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2008-10-27 10 percent owner
LIMIT LIMIT 2010-08-16 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2009-07-13 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2008-03-11 10 percent owner
LIMIT LIMIT 2008-10-22 10 percent owner
LIMIT LIMIT 2007-11-05 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2007-10-19 10 percent owner
LIMIT LIMIT 2021-03-30 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2024-03-12 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2021-04-29 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-03-10 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2020-07-16 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2021-02-09 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-02-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2022-05-10 10 percent owner & other: *Possible Member of 10% Group
LIMIT LIMIT 2021-10-26 10 percent owner & other: *Possible Member of 10% Group
LIMIT LIMIT 2021-06-01 10 percent owner & other: *Possible Member of 10% Group
LIMIT LIMIT 2022-11-03 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2021-07-27 director & 10 percent owner & other: Director by deputization
LIMIT LIMIT 2020-02-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-05-08 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2022-11-08 director & 10 percent owner & other: Director by deputization
LIMIT LIMIT 2020-02-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2022-11-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2022-11-08 director & 10 percent owner & other: Director by deputization
LIMIT LIMIT 2022-11-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-10-02 10 percent owner & other: Possible Member of 10% Group

James E Flynn Latest Holdings Summary

James E Flynn currently owns a total of 61 stocks. Among these stocks, James E Flynn owns 19,991,024 shares of Nuvalent Inc (NUVL) as of November 3, 2022, with a value of $1.6 Billion and a weighting of 43.65%. James E Flynn owns 2,236,700 shares of AveXis Inc (AVXS) as of February 17, 2016, with a value of $487 Million and a weighting of 13.31%. James E Flynn also owns 21,231,974 shares of Larimar Therapeutics Inc (LRMR) as of February 16, 2024, with a value of $204 Million and a weighting of 5.58%. The other 58 stocks AdaptHealth Corp (AHCO) , Shockwave Medical Inc (SWAV) , Mirum Pharmaceuticals Inc (MIRM) , Antares Pharma Inc (ATRS) , Audentes Therapeutics Inc (BOLD) , Revolution Medicines Inc (RVMD) , XenoPort Inc (XNPT) , Edgewise Therapeutics Inc (EWTX) , Alpine Immune Sciences Inc (ALPN) , Avadel Pharmaceuticals PLC (AVDL) , Arena Pharmaceuticals Inc (ARNA) , Rhythm Pharmaceuticals Inc (RYTM) , NxStage Medical Inc (NXTM) , Schrodinger Inc (SDGR) , Arvinas Inc (ARVN) , Constellation Pharmaceuticals Inc (CNST) , Vanda Pharmaceuticals Inc (VNDA) , Axogen Inc (AXGN) , Kiniksa Pharmaceuticals Ltd (KNSA) , Cabaletta Bio Inc (CABA) , Regenxbio Inc (RGNX) , Terns Pharmaceuticals Inc (TERN) , PepGen Inc (PEPG) , Nkarta Inc (NKTX) , Invuity Inc (IVTY) , Editas Medicine Inc (EDIT) , Annexon Inc (ANNX) , eHealth Inc (EHTH) , Catalyst Biosciences Inc (CBIO) , Rigel Pharmaceuticals Inc (RIGL) , SteadyMed Ltd (STDY) , CAS Medical Systems Inc (CASM) , Xeris Biopharma Holdings Inc (XERS) , Black Diamond Therapeutics Inc (BDTX) , Aclaris Therapeutics Inc (ACRS) , Generation Bio Co (GBIO) , Singular Genomics Systems Inc (OMIC) , Xilio Therapeutics Inc (XLO) , Societal CDMO Inc (SCTL) , Lumos Pharma Inc (LUMO) , CalciMedica Inc (CALC) , CytomX Therapeutics Inc (CTMX) , Alimera Sciences Inc (ALIM) , Syros Pharmaceuticals Inc (SYRS) , Proteon Therapeutics Inc (PRTO) , Neos Therapeutics Inc (NEOS) , Streamline Health Solutions Inc (STRM) , Frequency Therapeutics Inc (FREQ) , Oncorus Inc (ONCR) , Acutus Medical Inc (AFIB) , Homology Medicines Inc (FIXX) , Mallinckrodt PLC (MNKKQ) , Zafgen Inc (ZFGN) , aTyr Pharma Inc (ATYR) , Cyclacel Pharmaceuticals Inc (CYCC) , Dynavax Technologies Corp (DVAX) , The Medicines Co (MDCO) , Davis Select U.S. Equity ETF (DUSA) have a combined weighting of 37.46% among all his current holdings.

Latest Holdings of James E Flynn

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NUVL Nuvalent Inc 2022-11-03 19,991,024 79.95 1,598,282,369
AVXS AveXis Inc 2016-02-17 2,236,700 217.83 487,220,361
LRMR Larimar Therapeutics Inc 2024-02-16 21,231,974 9.62 204,251,590
AHCO AdaptHealth Corp 2024-03-12 13,257,940 11.52 152,731,469
SWAV Shockwave Medical Inc 2019-03-11 342,146 334.75 114,533,374
MIRM Mirum Pharmaceuticals Inc 2022-06-06 3,244,434 27.00 87,599,718
ATRS Antares Pharma Inc 2015-09-30 15,451,126 5.59 86,371,794
BOLD Audentes Therapeutics Inc 2016-07-25 1,403,654 59.97 84,177,130
RVMD Revolution Medicines Inc 2020-02-18 2,096,384 39.99 83,834,396
XNPT XenoPort Inc 2016-02-19 11,572,125 7.07 81,814,924
EWTX Edgewise Therapeutics Inc 2021-03-30 3,933,137 17.87 70,265,493
ALPN Alpine Immune Sciences Inc 2015-06-23 933,103 64.97 60,623,702
AVDL Avadel Pharmaceuticals PLC 2018-06-25 3,674,506 15.24 55,981,099
ARNA Arena Pharmaceuticals Inc 2007-10-15 512,564 99.99 51,251,274
RYTM Rhythm Pharmaceuticals Inc 2017-10-10 937,010 42.27 39,607,413
NXTM NxStage Medical Inc 2009-12-15 1,292,874 30.00 38,786,220
SDGR Schrodinger Inc 2020-02-10 1,596,167 21.64 34,541,054
ARVN Arvinas Inc 2018-10-01 1,233,734 26.49 32,681,614
CNST Constellation Pharmaceuticals Inc 2018-07-23 835,843 33.99 28,410,304
VNDA Vanda Pharmaceuticals Inc 2016-09-23 4,328,344 5.93 25,667,080
AXGN Axogen Inc 2016-07-21 3,000,000 8.07 24,210,000
KNSA Kiniksa Pharmaceuticals Ltd 2018-05-29 1,226,890 18.93 23,225,028
CABA Cabaletta Bio Inc 2019-10-29 1,628,506 12.14 19,770,063
RGNX Regenxbio Inc 2015-09-22 1,344,042 13.15 17,674,152
TERN Terns Pharmaceuticals Inc 2021-02-09 2,382,033 7.39 17,603,224
PEPG PepGen Inc 2022-05-10 953,626 17.71 16,888,716
NKTX Nkarta Inc 2020-07-14 2,419,872 6.33 15,317,790
IVTY Invuity Inc 2016-12-14 1,690,498 7.39 12,492,780
EDIT Editas Medicine Inc 2016-02-08 1,809,400 6.04 10,928,776
ANNX Annexon Inc 2020-07-28 1,617,828 6.03 9,755,503
EHTH eHealth Inc 2017-04-27 1,831,554 5.00 9,157,770
CBIO Catalyst Biosciences Inc 2018-03-08 1,113,222 7.67 8,537,856
RIGL Rigel Pharmaceuticals Inc 2011-05-26 6,742,289 1.01 6,809,712
STDY SteadyMed Ltd 2015-03-25 1,267,733 4.73 5,990,038
CASM CAS Medical Systems Inc 2017-01-26 2,358,636 2.45 5,778,658
XERS Xeris Biopharma Holdings Inc 2019-02-11 2,355,136 2.24 5,275,505
BDTX Black Diamond Therapeutics Inc 2020-02-03 778,790 6.24 4,859,650
ACRS Aclaris Therapeutics Inc 2019-06-27 4,123,266 1.15 4,741,756
GBIO Generation Bio Co 2020-06-16 1,186,215 3.31 3,926,372
OMIC Singular Genomics Systems Inc 2021-06-01 9,112,019 0.35 3,178,272
XLO Xilio Therapeutics Inc 2021-10-26 2,287,944 1.07 2,448,100
SCTL Societal CDMO Inc 2017-06-14 1,901,685 1.10 2,091,854
LUMO Lumos Pharma Inc 2021-01-08 784,568 2.57 2,016,340
CALC CalciMedica Inc 2020-09-29 377,265 5.06 1,908,961
CTMX CytomX Therapeutics Inc 2015-10-14 946,024 1.49 1,409,576
ALIM Alimera Sciences Inc 2015-12-08 391,870 3.10 1,214,797
SYRS Syros Pharmaceuticals Inc 2016-07-06 209,522 5.40 1,131,419
PRTO Proteon Therapeutics Inc 2017-11-30 30,622 33.41 1,023,081
NEOS Neos Therapeutics Inc 2015-07-28 858,332 1.15 987,082
STRM Streamline Health Solutions Inc 2015-12-17 1,875,500 0.52 965,883
FREQ Frequency Therapeutics Inc 2019-10-07 1,231,434 0.30 368,938
ONCR Oncorus Inc 2022-12-30 2,597,314 0.13 327,262
AFIB Acutus Medical Inc 2021-07-19 5,415,449 0.05 243,695
FIXX Homology Medicines Inc 2020-01-30 227,073 0.93 212,245
MNKKQ Mallinckrodt PLC 2018-05-09 8,308,455 0.02 166,169
ZFGN Zafgen Inc 2016-07-20 142,841 0.99 141,413
ATYR aTyr Pharma Inc 2015-05-12 36,538 1.91 69,605
CYCC Cyclacel Pharmaceuticals Inc 2008-03-11 84 1.70 143
DVAX Dynavax Technologies Corp 2008-10-22 0 12.10 0
MDCO The Medicines Co 2011-04-06 0 84.90 0
DUSA Davis Select U.S. Equity ETF 2011-03-22 0 39.99 0

Holding Weightings of James E Flynn


James E Flynn Form 4 Trading Tracker

According to the SEC Form 4 filings, James E Flynn has made a total of 1 transactions in Nuvalent Inc (NUVL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Nuvalent Inc is the acquisition of 650,000 shares on November 3, 2022, which cost James E Flynn around $22 Million.

According to the SEC Form 4 filings, James E Flynn has made a total of 0 transactions in AveXis Inc (AVXS) over the past 5 years. The most-recent trade in AveXis Inc is the acquisition of 750,317 shares on February 17, 2016, which cost James E Flynn around $15 Million.

According to the SEC Form 4 filings, James E Flynn has made a total of 2 transactions in Larimar Therapeutics Inc (LRMR) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Larimar Therapeutics Inc is the acquisition of 4,290,617 shares on February 16, 2024, which cost James E Flynn around $38 Million.

More details on James E Flynn's insider transactions can be found in the Insider Trading History of James E Flynn table.

Insider Trading History of James E Flynn

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James E Flynn Trading Performance

GuruFocus tracks the stock performance after each of James E Flynn's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James E Flynn is -0.32%. GuruFocus also compares James E Flynn's trading performance to market benchmark return within the same time period. The performance of stocks bought by James E Flynn within 3 months outperforms 20 times out of 69 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James E Flynn's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James E Flynn

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
25 out of 65 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 1.94 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 1.32 LIMIT LIMIT LIMIT LIMIT LIMIT

James E Flynn Ownership Network

Ownership Network List of James E Flynn

No Data

Ownership Network Relation of James E Flynn

Insider Network Chart

James E Flynn Owned Company Details

What does Oncorus Inc do?

Who are the key executives at Oncorus Inc?

James E Flynn is the director & 10 percent owner & other: *Possible Member of 10% Group of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and CFO and Treasurer Rick Wanstall .

Oncorus Inc (ONCR) Insider Trades Summary

Over the past 18 months, James E Flynn made 4 insider transaction in Oncorus Inc (ONCR) with a net sale of 551,663.

In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 551,663 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 551,663 shares.

Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Oncorus Inc Insider Transactions

No Available Data

James E Flynn Mailing Address

Above is the net worth, insider trading, and ownership report for James E Flynn. You might contact James E Flynn via mailing address: 780 Third Avenue, 37th Floor, New York Ny 10017.

Discussions on James E Flynn

No discussions yet.